Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus TETRAMED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus TETRAMED.
ACTICLATE CAP vs TETRAMED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Tetracycline inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life is 12–15 hours in adults with normal renal function; in renal impairment (CrCl <30 mL/min), half-life may extend to >30 hours, requiring dose adjustment.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; minor metabolic clearance accounts for 10%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic